IN2014KN01713A - - Google Patents

Info

Publication number
IN2014KN01713A
IN2014KN01713A IN1713KON2014A IN2014KN01713A IN 2014KN01713 A IN2014KN01713 A IN 2014KN01713A IN 1713KON2014 A IN1713KON2014 A IN 1713KON2014A IN 2014KN01713 A IN2014KN01713 A IN 2014KN01713A
Authority
IN
India
Prior art keywords
antibody
cancer
amino acid
acid sequence
seq
Prior art date
Application number
Other languages
English (en)
Inventor
Shinichi Kobayashi
Fumiyoshi Okano
Takanori Saito
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of IN2014KN01713A publication Critical patent/IN2014KN01713A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN1713KON2014 2012-02-21 2013-02-21 IN2014KN01713A (forum.php)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012035484 2012-02-21
PCT/JP2013/054337 WO2013125636A1 (ja) 2012-02-21 2013-02-21 癌の治療及び/又は予防用医薬組成物

Publications (1)

Publication Number Publication Date
IN2014KN01713A true IN2014KN01713A (forum.php) 2015-10-23

Family

ID=49005813

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1713KON2014 IN2014KN01713A (forum.php) 2012-02-21 2013-02-21

Country Status (16)

Country Link
US (1) US9273130B2 (forum.php)
EP (1) EP2818482B1 (forum.php)
JP (1) JP6187255B2 (forum.php)
KR (1) KR102009238B1 (forum.php)
CN (1) CN104169303B (forum.php)
AU (1) AU2013223143B2 (forum.php)
CA (1) CA2864864C (forum.php)
DK (1) DK2818482T3 (forum.php)
ES (1) ES2739612T3 (forum.php)
HU (1) HUE044611T2 (forum.php)
IN (1) IN2014KN01713A (forum.php)
MX (1) MX360208B (forum.php)
PL (1) PL2818482T3 (forum.php)
PT (1) PT2818482T (forum.php)
RU (1) RU2632645C2 (forum.php)
WO (1) WO2013125636A1 (forum.php)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102171570B (zh) 2008-08-05 2014-10-15 东丽株式会社 用于检测癌的方法
MX341883B (es) * 2008-08-05 2016-09-07 Toray Industries Composicion farmaceutica para el tratamiento y prevencion de canceres.
BR112012018949A2 (pt) * 2010-02-04 2020-09-01 Toray Industries Composições farmacêuticas, anticorpos, combinação farmacêutica, métodos para o tratamento e/ou prevenção de um câncer, usos de uma composição farmacêutica, uso5 de um anticorpo e uso de uma combinação farmacêutica
MX351414B (es) * 2011-08-04 2017-10-13 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico.
HUE033628T2 (en) 2011-08-04 2017-12-28 Toray Industries Method for detecting pancreatic cancer
HUE034736T2 (en) 2012-02-21 2018-02-28 Toray Industries A pharmaceutical composition for the treatment and / or prevention of cancer
AU2013241036B2 (en) * 2012-03-30 2017-07-20 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of liver cancer
BR112014024209A2 (pt) 2012-03-30 2018-04-10 Toray Industries composição farmacêutica, agente farmacêutico e método de tratamento e/ou prevenção de cancêr da vesicula biliar
PL2876447T3 (pl) 2012-07-19 2020-05-18 Toray Industries, Inc. Sposób wykrywania nowotworu
US9772332B2 (en) 2012-07-19 2017-09-26 Toray Industries, Inc. Method for detecting CAPRIN-1 in a biological sample
MY181648A (en) 2012-08-24 2020-12-30 Univ California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
PL3031826T3 (pl) 2013-08-09 2019-03-29 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
TWI805127B (zh) 2016-03-04 2023-06-11 美商Jn生物科學有限責任公司 針對tigit之抗體
AU2017289270B2 (en) 2016-06-27 2023-05-04 The Regents Of The University Of California Cancer treatment combinations
CN109843327B (zh) 2016-07-07 2022-05-13 小利兰·斯坦福大学托管委员会 抗体佐剂缀合物
AU2017348734B2 (en) 2016-10-28 2024-09-26 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
AU2019242520A1 (en) 2018-03-30 2020-10-29 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
CN113993549A (zh) 2019-03-15 2022-01-28 博尔特生物治疗药物有限公司 靶向her2的免疫缀合物
EP3983082A1 (en) 2019-06-13 2022-04-20 Bolt Biotherapeutics, Inc. Aminobenzazepine compounds, immunoconjugates, and uses thereof
WO2021067242A1 (en) 2019-09-30 2021-04-08 Bolt Biotherapeutics, Inc. Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
MX2022004875A (es) 2019-10-25 2022-06-17 Bolt Biotherapeutics Inc Inmunoconjugados de tienoazepina, inmunoconjugados y usos de estos.
CA3175279A1 (en) 2020-03-12 2021-09-16 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
WO2021182573A1 (ja) 2020-03-12 2021-09-16 東レ株式会社 癌の治療及び/又は予防のための医薬品
KR20220152309A (ko) 2020-03-12 2022-11-15 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
WO2021182570A1 (ja) 2020-03-12 2021-09-16 東レ株式会社 癌の治療及び/又は予防のための医薬品
WO2021182572A1 (ja) 2020-03-12 2021-09-16 東レ株式会社 癌の治療及び/又は予防のための医薬品
JP2023524271A (ja) 2020-05-08 2023-06-09 ボルト バイオセラピューティクス、インコーポレーテッド エラスターゼ-基質ペプチドリンカーイムノコンジュゲート、及びそれらの使用
CN115698068A (zh) 2020-06-02 2023-02-03 艾库斯生物科学有限公司 抗tigit抗体
MX2023001679A (es) 2020-08-13 2023-02-22 Bolt Biotherapeutics Inc Inmunoconjugados de pirazolazepina y usos de estos.
CN117545508A (zh) 2021-06-23 2024-02-09 东丽株式会社 用于癌的治疗和/或预防的药品
US20250228937A1 (en) 2021-06-23 2025-07-17 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
KR20240042416A (ko) 2021-07-27 2024-04-02 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
JPWO2023008462A1 (forum.php) 2021-07-27 2023-02-02
AU2022316644A1 (en) * 2021-07-27 2024-02-29 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
US20250281630A1 (en) 2021-09-03 2025-09-11 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
EP4422697A1 (en) 2021-10-29 2024-09-04 Bolt Biotherapeutics, Inc. Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof
EP4548932A1 (en) 2022-06-30 2025-05-07 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
AU2023329563A1 (en) 2022-08-24 2025-02-27 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
EP4578457A1 (en) 2022-08-24 2025-07-02 Toray Industries, Inc. Pharmaceutical for treating and/or preventing cancer
EP4578459A1 (en) 2022-08-24 2025-07-02 Toray Industries, Inc. Pharmaceutical product for treatment and/or prevention of cancer
AU2023334695A1 (en) 2022-08-30 2025-02-27 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CN119768184A (zh) 2022-08-30 2025-04-04 东丽株式会社 用于癌的治疗和/或预防的药品
AU2023411604A1 (en) 2022-12-23 2025-06-26 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
WO2024173387A1 (en) 2023-02-14 2024-08-22 Bolt Biotherapeutics, Inc. Aza-benzazepine immunoconjugates, and uses thereof
WO2024186626A1 (en) 2023-03-03 2024-09-12 Bolt Biotherapeutics, Inc. Aza-bicyclic sting agonist immunoconjugates, and uses thereof
WO2025058000A1 (ja) * 2023-09-13 2025-03-20 東レ株式会社 癌の治療、予防及び/又は診断用医薬組成物

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1996002576A1 (fr) 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Anticorps humain reconstitue contre l'interleukine-8 humaine
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
KR20010042435A (ko) 1998-04-03 2001-05-25 나가야마 오사무 인간조직인자(티에프)에 대한 인간형화항체 및인간형화항체의 제조방법
US20030118599A1 (en) 1999-04-02 2003-06-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
RU2234942C2 (ru) 1998-07-14 2004-08-27 Корикса Корпорейшн Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид
CZ2001149A3 (cs) 1998-07-14 2002-02-13 Corixa Corporation Prostředky a způsoby pro terapii a diagnostiku karcinomu prostaty
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6335170B1 (en) 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
JP2002540790A (ja) 1999-04-02 2002-12-03 コリクサ コーポレイション 肺癌の治療および診断のための化合物ならびにその使用のための方法
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
JP2003528587A (ja) 1999-10-29 2003-09-30 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド 27個のヒト分泌タンパク質
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
AU2001261007A1 (en) 2000-03-29 2001-10-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
ATE378403T1 (de) 2000-11-30 2007-11-15 Medarex Inc Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20040029114A1 (en) 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
RU2306952C2 (ru) 2001-01-31 2007-09-27 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами
AU2002311787A1 (en) 2001-03-28 2002-10-15 Zycos Inc. Translational profiling
WO2002083070A2 (en) 2001-04-10 2002-10-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2002092812A1 (en) 2001-05-11 2002-11-21 Kirin Beer Kabushiki Kaisha ARTIFICIAL HUMAN CHROMOSOME CONTAINING HUMAN ANTIBODY μ LIGHT CHAIN GENE
WO2002092001A2 (en) 2001-05-11 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030190640A1 (en) 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20040258678A1 (en) 2002-02-22 2004-12-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20050003390A1 (en) 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
US20040126379A1 (en) 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
US20060121029A1 (en) 2002-08-30 2006-06-08 Hiroshi Shiku Method and composition for regulating the activity of regulatory t cells
EP2311870A1 (en) 2002-11-26 2011-04-20 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2004076682A2 (en) 2003-02-26 2004-09-10 Surromed, Inc. Targets for controlling cellular growth and for diagnostic methods
US20050202451A1 (en) 2003-04-29 2005-09-15 Burczynski Michael E. Methods and apparatuses for diagnosing AML and MDS
CA2528669A1 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070048738A1 (en) 2003-07-14 2007-03-01 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
US20050032113A1 (en) 2003-07-17 2005-02-10 Mitsubishi Pharma Corporation Membrane protein library for proteome analysis and method for preparing same
EP2361929A1 (en) 2004-01-26 2011-08-31 Debiovision Inc. Neoplasm-specific polypeptides and their use
JP4734319B2 (ja) 2004-03-19 2011-07-27 イムクローン・リミテッド・ライアビリティ・カンパニー ヒト抗上皮成長因子受容体抗体
US7858753B2 (en) 2004-03-30 2010-12-28 Glaxo Group Limited Immunoglobulins
WO2005100998A2 (en) 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
DE102004026135A1 (de) 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
WO2006002378A2 (en) 2004-06-23 2006-01-05 Avalon Pharmaceuticals Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
AR050418A1 (es) 2005-01-21 2006-10-25 Genentech Inc Dosificacion fija de anticuerpos her
JP5006802B2 (ja) 2005-02-18 2012-08-22 チルドレンズ メディカル センター コーポレイション 上皮由来の癌診断および予後診断のためのバイオマーカーとしてのCyr61
WO2006099126A2 (en) 2005-03-11 2006-09-21 Ciphergen Biosystems, Inc. Biomarkers for ovarian cancer and endometrial cancer: hepcidin
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Herceptin(登録商標)補助療法
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
CA2642342A1 (en) 2006-02-14 2007-08-23 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US20100015724A1 (en) 2006-08-17 2010-01-21 Peter Hornbeck Lysine acetylation sites
US20080107668A1 (en) 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2008031041A2 (en) 2006-09-07 2008-03-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
WO2008059252A2 (en) 2006-11-15 2008-05-22 Oxford Biomedica (Uk) Limited Methods and composition fro t cell receptors which recognize 5t4 antigen
US9249409B2 (en) 2007-10-25 2016-02-02 Toray Industries, Inc. Method for detection of cancer
JP5663834B2 (ja) 2008-03-14 2015-02-04 東ソー株式会社 遺伝子組換え抗体の製造方法
IL295098B1 (en) 2008-03-18 2025-08-01 Genentech Inc Combinations of trastuzumab-DM1-MCC and 5-FU for use in the treatment of ERBB2-expressing cancers
RU2511315C2 (ru) * 2008-07-31 2014-04-10 Синомикс, Инк. Композиции, содержащие усилители сладкого вкуса, и способы их получения
CN102171570B (zh) 2008-08-05 2014-10-15 东丽株式会社 用于检测癌的方法
BRPI0912462B1 (pt) 2008-08-05 2022-03-22 Toray Industries, Inc Uso de um agente indutor de imunidade, uso de um polipeptídeo e uso de um vetor recombinante
MX341883B (es) 2008-08-05 2016-09-07 Toray Industries Composicion farmaceutica para el tratamiento y prevencion de canceres.
CN102597001B (zh) 2009-08-19 2014-07-30 默克专利有限公司 在ffpe材料中用于检测整联蛋白复合体的抗体
JP5746183B2 (ja) 2009-09-22 2015-07-08 プロビオゲン アーゲー 特定のグリカン構造を含有する分子を生成する方法
RU2418587C1 (ru) * 2010-01-21 2011-05-20 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО "НижГМА Росздрава") Способ лечения злокачественных опухолей головного мозга
CN102822199B (zh) 2010-02-04 2014-10-15 东丽株式会社 癌的治疗和/或预防用药物组合物
KR101843807B1 (ko) 2010-02-04 2018-03-30 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
EP2532366B1 (en) 2010-02-04 2016-09-07 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
DK2532364T3 (en) * 2010-02-04 2016-08-15 Toray Industries PHARMACEUTICAL COMPOSITION CONTAINING ANTI CAPRIN-1 ANTIBODIES FOR TREATMENT AND / OR PREVENTION OF CANCER
BR112012018949A2 (pt) 2010-02-04 2020-09-01 Toray Industries Composições farmacêuticas, anticorpos, combinação farmacêutica, métodos para o tratamento e/ou prevenção de um câncer, usos de uma composição farmacêutica, uso5 de um anticorpo e uso de uma combinação farmacêutica
CN102821788B (zh) * 2010-02-04 2016-11-16 东丽株式会社 癌的治疗和/或预防用药物组合物
WO2012005550A2 (ko) 2010-07-08 2012-01-12 강원대학교산학협력단 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법
WO2012013609A1 (en) 2010-07-26 2012-02-02 Bioréalités S.A.S. Methods and compositions for liver cancer therapy
JP2012035484A (ja) 2010-08-06 2012-02-23 Tombow Pencil Co Ltd 塗膜転写具
HUE033628T2 (en) 2011-08-04 2017-12-28 Toray Industries Method for detecting pancreatic cancer
MX351414B (es) 2011-08-04 2017-10-13 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico.
WO2013018894A1 (ja) 2011-08-04 2013-02-07 東レ株式会社 癌の治療及び/又は予防用医薬組成物
AU2013241036B2 (en) 2012-03-30 2017-07-20 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of liver cancer
BR112014024209A2 (pt) * 2012-03-30 2018-04-10 Toray Industries composição farmacêutica, agente farmacêutico e método de tratamento e/ou prevenção de cancêr da vesicula biliar

Also Published As

Publication number Publication date
KR102009238B1 (ko) 2019-08-09
AU2013223143A1 (en) 2014-09-11
EP2818482B1 (en) 2019-05-22
CN104169303B (zh) 2018-05-29
DK2818482T3 (da) 2019-07-15
US9273130B2 (en) 2016-03-01
CA2864864C (en) 2020-05-12
MX360208B (es) 2018-10-24
WO2013125636A1 (ja) 2013-08-29
JP6187255B2 (ja) 2017-08-30
BR112014021101A2 (pt) 2022-03-22
AU2013223143B2 (en) 2017-12-21
HUE044611T2 (hu) 2019-11-28
PL2818482T3 (pl) 2019-11-29
EP2818482A1 (en) 2014-12-31
KR20140130668A (ko) 2014-11-11
CN104169303A (zh) 2014-11-26
US20150004171A1 (en) 2015-01-01
CA2864864A1 (en) 2013-08-29
EP2818482A4 (en) 2015-10-07
MX2014009748A (es) 2014-11-14
RU2632645C2 (ru) 2017-10-06
RU2014138040A (ru) 2016-04-10
ES2739612T3 (es) 2020-02-03
JPWO2013125636A1 (ja) 2015-07-30
PT2818482T (pt) 2019-08-06

Similar Documents

Publication Publication Date Title
IN2014KN01713A (forum.php)
IN2014KN01714A (forum.php)
IN2014KN01716A (forum.php)
IN2014KN01715A (forum.php)
MX2014001375A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2014001372A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico.
MX2012008999A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX358224B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer de higado.
WO2017009843A3 (en) Compositions, articles of manufacture and methods for treating cancer
MX360671B (es) Composición farmacéutica para el tratamiento y/o prevención del cáncer.
NZ713461A (en) Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
NZ761006A (en) Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
MX357965B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer de vesicula biliar.
NZ705370A (en) Fcγriib-specific fc region variant
MY167232A (en) Polypeptides binding to human complement c5
MX2016008989A (es) Fragmentos mutantes de ospa y metodos y usos relacionados con estos.
IN2014DN09963A (forum.php)
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
EA201790341A1 (ru) Анти-ск8 антитела для применения в лечении рака
GB201118201D0 (en) Novel peptides
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита
WO2014039074A3 (en) Therapeutic compositions and related methods